0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessPROFILER has recruited 5,991 patients in 10 years, MOST and MOST Plus 875 patients since 2014 and MEGAMOST 172 patients since 2020, and are still ongoing. We provide a description of the local, national and international implications of these initiatives, and we review the results of the sorafenib and olaparib cohorts.
Loïc Verlingue, Marine Desevre, M. Polito, Gwenaëlle Garin, Christine Rodriguez, Qing Wang, Olivier Trédan, David Pérol, Isabelle Ray‐Coquard, Sylvie Chabaud, Jean Yves Blay (2024). The French multicentric molecular analysis platforms and personalized medicine trials MOST, MOST Plus and MEGAMOST. , 63, DOI: https://doi.org/10.2340/1651-226x.2024.32745.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2024
Authors
11
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.2340/1651-226x.2024.32745
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
